Facioscapulohumeral Muscular Dystrophy Fshd clinical trials

Explore recruiting facioscapulohumeral muscular dystrophy fshd clinical trials.

Recruiting facioscapulohumeral muscular dystrophy fshd studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Facioscapulohumeral Muscular Dystrophy Fshd trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Adult Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)

Netherlands, Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled, 48-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)

Italy, Spain, France, Germany, Netherlands, Denmark

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Pharmacodynamics, Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy

Italy, Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DUX4 in Adult Patients With Facioscapulohumeral Muscular Dystrophy Type 1

Netherlands, Spain, Germany, Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)

Italy, France, Germany, Spain, Denmark, Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 48-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Subjects with Facioscapulohumeral Muscular Dystrophy (FSHD) with Open-Label Extension (OLE)

Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Facioscapulohumeral Muscular Dystrophy Fshd trials by city

Facioscapulohumeral Muscular Dystrophy Fshd in Toronto Facioscapulohumeral Muscular Dystrophy Fshd in Vancouver Facioscapulohumeral Muscular Dystrophy Fshd in Montreal Facioscapulohumeral Muscular Dystrophy Fshd in Calgary Facioscapulohumeral Muscular Dystrophy Fshd in Edmonton Facioscapulohumeral Muscular Dystrophy Fshd in Ottawa Facioscapulohumeral Muscular Dystrophy Fshd in Winnipeg Facioscapulohumeral Muscular Dystrophy Fshd in Quebec City Facioscapulohumeral Muscular Dystrophy Fshd in Hamilton Facioscapulohumeral Muscular Dystrophy Fshd in Kitchener Facioscapulohumeral Muscular Dystrophy Fshd in London Facioscapulohumeral Muscular Dystrophy Fshd in Halifax Facioscapulohumeral Muscular Dystrophy Fshd in New York Facioscapulohumeral Muscular Dystrophy Fshd in Los Angeles Facioscapulohumeral Muscular Dystrophy Fshd in Chicago Facioscapulohumeral Muscular Dystrophy Fshd in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease